Clinical Trials in Victoria, Chile

7 recruiting

Showing 18 of 8 trials

Recruiting
Phase 3

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

Cardiovascular Disease
AstraZeneca15,100 enrolled1333 locationsNCT07000357
Recruiting
Phase 3

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Chronic Kidney Disease and Hypertension
AstraZeneca5,000 enrolled761 locationsNCT06742723
Recruiting
Phase 3

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca5,000 enrolled920 locationsNCT06283966
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis
AstraZeneca320 enrolled144 locationsNCT07276581
Recruiting
Phase 3

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Heart Failure and Impaired Kidney Function
AstraZeneca4,800 enrolled845 locationsNCT06307652
Recruiting
Phase 2

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
Immunovant Sciences GmbH56 enrolled86 locationsNCT06980805
Recruiting
Phase 3

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
AbbVie1,000 enrolled369 locationsNCT05843643
Recruiting
Phase 2

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

SclerodermaSystemic Sclerosis (SSc)
Zura Bio Inc80 enrolled51 locationsNCT06843239